Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 9/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30405736 | 0.84 | HTR6 (0.39) | PTGDRPTGDR2SRCHTR6L3MBTL1 | |
| SCHEMBL25424320 | 0.84 | HTR6 (0.39) | PTGDRPTGDR2SRCHTR6L3MBTL1 | |
| SCHEMBL31579098 | 0.83 | KDM4E (0.38) | PTGDRPTGDR2SRCHTR6BRD4 | |
| SCHEMBL31578890 | 0.82 | PTGDR (0.37) | PTGDRPTGDR2SRCHTR6BRD4 | |
| SCHEMBL25423168 | 0.81 | SRC (0.41) | PTGDRPTGDR2SRCHTR6BRD4 | |
| SCHEMBL25420154 | 0.75 | MTNR1B (0.54) | SRCHTR6ACLY | |
| SCHEMBL25421448 | 0.73 | CA12 (0.51) | SRCHTR6LMNAPPARGPPARA | |
| SCHEMBL31023100 | 0.72 | AR (0.42) | SRCL3MBTL1LMNA | |
| SCHEMBL24015624 | 0.72 | HTR6 (0.52) | PTGDRPTGDR2SRCHTR6BRD4 | |
| SCHEMBL597369 | 0.69 | HTR6 (0.46) | PTGDRPTGDR2SRCHTR6BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022120-A1 | Inhibitors of MENIN-MLL Interaction | BALA THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, BMI1 | PTGDR 4314/4885PTGDR2 4063/4885SRC 2212/4885 |
| US-20260022120-A1 | Inhibitors of MENIN-MLL Interaction | MEN1, MLLT1, MLLT3 | PTGDR 4531/4885PTGDR2 4556/4885SRC 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.